Comparing Early and Standard Timing of Aspirin After Clot-Dissolving Treatment for Stroke
Compares giving aspirin 2 hours versus 24 hours after thrombolysis in ischemic stroke.
Plain-language title generated from the registry record
Registry title: Early Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction（ELASTIC）
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 who had a stroke caused by a blocked brain artery and received the clot-dissolving drug rt PA within 3 hours. It compares aspirin 100mg at 2 hours versus 24 hours after.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Acute stroke from a blocked brain artery. Signs of brain dysfunction lasting more than 1 hour. A CT scan shows no bleeding in the brain.
- Earlier treatment
- Must have received rt PA clot-dissolving treatment within 3 hours (including 3 hours) of onset. Must not be taking blood-thinning (anticoagulant) tablets.
Main reasons for not taking part
- Older than 65 years
- Stroke started more than 3 hours ago
- Disorder of consciousness, or NIHSS score of 20 or more
- Atrial fibrillation, or stroke clearly caused by a clot from the heart
- Severe swallowing problems, unable to take medicine by mouth
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07563673, who can take part
Where in China
- Beijng Chao-Yang Hospital, Capital Medical UniversityBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Chao Yang Hospital
- Trial code
- NCT07563673
- Record updated
- 8 May 2026
- Original description
This study evaluates whether early administration of low-dose aspirin (100mg) at 2 hours post-intravenous thrombolysis, compared to the standard timing of 24 hours, improves functional outcomes in patients with acute ischemic stroke. Intravenous thrombolysis is effective for very early treatment of acute ischemic stroke. However, current guidelines recommend starting antiplatelet therapy 24 hours after thrombolysis to avoid symptomatic intracranial hemorrhage (SICH), a recommendation not based on prospective clinical studies. Early re-occlusion of recanalized arteries due to platelet aggregation occurs in 14-34% of cases and is associated with poor prognosis. The average incidence of SICH is 2.4%, with fatal SICH occurring in only 0.28%. Thus, the impact of re-occlusion on poor prognosis may outweigh the risk of SICH. In this prospective, randomized, open-label trial with blinded endpoint evaluation, participants are assigned to receive aspirin 100mg either at 2 hours (early group) or at 24 hours (standard group) after thrombolysis. The primary outcome is the proportion of patients with a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-2 at 3 months. Safety outcomes include the incidence of SICH and all-cause mortality at 3 months. This study will provide clinical evidence regarding the optimal timing for initiating antiplatelet therapy after thrombolysis in acute ischemic stroke.Read full original descriptionShow less
Safety and Efficacy of Treatment With Early Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction (ELASTIC): A Randomized, Open-label, Blinded Endpoint, Clinical Trial
This study evaluates whether early administration of low-dose aspirin (100mg) at 2 hours post-intravenous thrombolysis, compared to the standard timing of 24 hours, improves functional outcomes in patients with acute ischemic stroke. Intravenous thrombolysis is effective for very early treatment of acute ischemic stroke. However, current guidelines recommend starting antiplatelet therapy 24 hours after thrombolysis to avoid symptomatic intracranial hemorrhage (SICH), a recommendation not based on prospective clinical studies. Early re-occlusion of recanalized arteries due to platelet aggregation occurs in 14-34% of cases and is associated with poor prognosis. The average incidence of SICH is 2.4%, with fatal SICH occurring in only 0.28%. Thus, the impact of re-occlusion on poor prognosis may outweigh the risk of SICH. In this prospective, randomized, open-label trial with blinded endpoint evaluation, participants are assigned to receive aspirin 100mg either at 2 hours (early group) or at 24 hours (standard group) after thrombolysis. The primary outcome is the proportion of patients with a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-2 at 3 months. Safety outcomes include the incidence of SICH and all-cause mortality at 3 months. This study will provide clinical evidence regarding the optimal timing for initiating antiplatelet therapy after thrombolysis in acute ischemic stroke.
Inclusion: Age range: 18-65 years old; Receive rt PA thrombolytic therapy within 3 hours (including 3 hours) of onset; Signs of brain dysfunction lasting for more than 1 hour; CT imaging excludes cerebral hemorrhage, and there are no imaging changes corresponding to the patient's physical signs.
Exclusion: Severe swallowing difficulties, unable to take medication orally; Oral anticoagulant medication is currently being taken; Accompanied by consciousness disorders, or NIHSS ≥ 20 points; Accompanied by severe infection or evidence of severe infection; Age>65 years old; Onset time>3 hours; CT shows' high-density shadow of middle cerebral artery '; Accompanied by atrial fibrillation or clearly identified as cardioembolic embolism; Refusal to sign the informed consent form for this study; Exclusion criteria for other traditional intravenous thrombolysis.